

Expres² platform licensed by Boston Children's Hospital

September 29, 2015

HORSHOLM, September 29 2015- Expres²ion Biotechnologies, a private Danish company, ("Expres²ion") announced today the execution with Boston Children's Hospital ("Boston Children's"), located in Boston, Massachusetts, USA, of a non-exclusive research license agreement to use Expres²ion's proprietary recombinant protein expression platform Expres²for Boston Children's academic research. Boston Children's is the pediatric teaching affiliate of Harvard Medical School.

The Expres² platform is being used by top academic and top private industry teams to solve protein expression challenges. The system has proven to be instrumental in advancing research in neglected diseases, including malaria research and vaccine projects, where other expression systems have failed to yield the native properties of the parasite proteins – or even failed to express the proteins. Expres² provides high quality, very homogenous expressed proteins, qualities that are needed in structural biology studies.

"Expres²ion aims to support the development of novel drugs through solving protein production challenges. Our proprietary technology platform can deliver protein for laboratory use and is also compatible with current Good Manufacturing Practice (cGMP). This interaction with Boston Children's is part of our strategy to support top academic teams in protein expression. It is our hope that this license will advance the understanding of relevant immunological processes and of malaria vaccine candidates." said Wian de Jongh, Ph. D., Chief Scientific Officer, Expres²ion.

About Expres²ion Biotechnologies

Expres²ion Biotechnologies is a world leading CRO specializing in developing cell lines and processes based on *Drosophila* S2 cells. Our company has a proprietary and complete S2 recombinant protein expression platform: Expres², which was developed over more than ten years. Expres² is a uniquely successful tool for non-viral insect-cell based expression, and we are the only company with in-depth practical experience in how to use it – both in preclinical development and in clinical trials. The Expres² platform is excellent in all phases of drug discovery, R&D and manufacturing as it offers fast access to protein and easy establishment of stable polyclonal pools. This results in high protein-expression levels with a regulatory friendly expression system.

For further information:

Expres²ion Biotechnologies ApS.,
Sancha Salgueiro, TEL: +45-41666121, sas@expres2ionbio.com,
<http://www.expres2ionbio.com>
SCION Science Park
Agern Alle 1
2970 Horsholm, Denmark